Publicaciones (20) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. 68Ga-PSMA PET/CT in prostate cancer

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 2, pp. 130-138

  2. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [ 18 F]FDG and sodium [ 18 F]fluoride PET

    BMC Cancer, Vol. 18, Núm. 1

  3. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217

  4. Amyloid PET in neurodegenerative diseases with dementia

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 6, pp. 397-406

  5. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1470-1486

  6. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1557-1566

  7. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1534-1545

  8. Clinical utility of FDG-PET for the clinical diagnosis in MCI

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1497-1508

  9. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1509-1525

  10. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1546-1556

  11. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1522-1528

  12. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1487-1496

  13. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1526-1533

  14. Human serum albumin nanoparticles for ocular delivery of bevacizumab

    International Journal of Pharmaceutics, Vol. 541, Núm. 1-2, pp. 214-223

  15. Increased oral bioavailability of resveratrol by its encapsulation in casein nanoparticles

    International Journal of Molecular Sciences, Vol. 19, Núm. 9

  16. PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy

    Journal of Controlled Release, Vol. 276, pp. 125-139

  17. Phantom, clinical, and texture indices evaluation and optimization of a penalized-likelihood image reconstruction method (Q.Clear) on a BGO PET/CT scanner

    Medical Physics, Vol. 45, Núm. 7, pp. 3214-3222

  18. Radium-223 in the treatment of bone metastasis in patients with castration-resistant prostate cancer. Review and procedure

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 5, pp. 330-337

  19. Role of amino-acid PET in high-grade gliomas: Limitations and perspectives

    Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 62, Núm. 3, pp. 254-266

  20. Significant dose reduction is feasible in FDG PET/CT protocols without compromising diagnostic quality

    Physica Medica, Vol. 46, pp. 134-139